Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Fox Chase Cancer Center
ClinicalTrials.gov Identifier:
NCT00352638
First received: July 13, 2006
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

RATIONALE: Printed educational materials and counseling by telephone may improve colorectal cancer screening compliance in brothers and sisters of patients with colorectal cancer.

PURPOSE: This randomized phase III trial is studying standard or personalized printed educational materials with or without telephone counseling to compare how well they work in increasing colorectal cancer screening compliance in brothers and sisters of patients with colorectal cancer.


Condition Intervention Phase
Colorectal Cancer
Other: counseling intervention
Other: educational intervention
Other: study of socioeconomic and demographic variables
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Official Title: Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients

Resource links provided by NLM:


Further study details as provided by Fox Chase Cancer Center:

Primary Outcome Measures:
  • Colorectal cancer screening compliance [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Impact on movement in stage of adoption [ Designated as safety issue: No ]
  • Increased knowledge and attitudes [ Designated as safety issue: No ]
  • Cost [ Designated as safety issue: No ]

Estimated Enrollment: 660
Study Start Date: August 2005
Study Completion Date: November 2013
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Compare the impact of 3 interventions (generic educational print intervention, tailored educational print intervention, or tailored educational print intervention plus telephone counseling) on colorectal cancer screening behaviors and intentions among siblings at increased familial risk for colorectal cancer.

Secondary

  • Determine whether demographic factors, medical access, physician recommendation at baseline, and proband (patient) characteristics (e.g., stage of disease) moderate the impact of the interventions on colorectal screening.
  • Evaluate whether knowledge, attitude, and physician recommendation variables mediate the association between the interventions and colorectal screening, and determine whether these variables are impacted by the interventions.
  • Analyze the cost of each intervention.

OUTLINE: This is a randomized, controlled, cohort, multicenter study. Participants are stratified according to study site. Participants are randomized to 1 of 3 intervention arms.

  • Arm I: Participants receive generic educational print intervention approximately 1 week after completing the baseline survey.
  • Arm II: Participants receive tailored educational print intervention within 10 days after completing the baseline survey and a tailored newsletter 1 month after completing the baseline survey.
  • Arm III: Participants receive tailored educational print intervention approximately 14-18 days after completing the baseline survey. Participants undergo a telephone counseling session within 2 weeks after receiving the tailored print intervention and receive a tailored newsletter 1 month after completing the baseline survey.

After study completion, participants are followed at 6 months and/or 1 year.

PROJECTED ACCRUAL: A total of 660 participants will be accrued for this study.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Sibling of a patient diagnosed with adenocarcinoma of the colon or rectum

    • Patient (proband) must meet the following criteria:

      • Diagnosed in 1999 or later
      • Currently living
      • Seen in Community Clinical Oncology Program member hospital
      • 60 and under at diagnosis
  • No history of hereditary cancer syndrome (e.g., familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer) (patient and sibling)
  • No history of colorectal cancer or colorectal polyps (sibling)
  • No history of inflammatory bowel disease (patient and sibling)

PATIENT CHARACTERISTICS:

  • Age 40 and over OR within 10 years of proband's (patient's) age at diagnosis
  • English speaking

PRIOR CONCURRENT THERAPY:

  • No prior colorectal cancer screening

    • May have undergone prior screening provided they have not followed, or do not plan to follow, physician's recommendation for screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00352638

Locations
United States, Delaware
Helen F. Graham Cancer Center at Christiana Care
Newark, Delaware, United States, 19713
United States, District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Florida
H. Lee Moffitt Cancer Center CCOP Research Base
Tampa, Florida, United States, 33612
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
United States, New Jersey
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, United States, 08822
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Marlton, New Jersey, United States, 08053
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare
Vineland, New Jersey, United States, 08360
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Pennsylvania
PinnacleHealth Regional Cancer Center at Polyclinic Hospital
Harrisburg, Pennsylvania, United States, 17105-8700
St. Mary Regional Cancer Center
Langhorne, Pennsylvania, United States, 19047
Fox Chase Cancer Center CCOP Research Base
Philadelphia, Pennsylvania, United States, 19140
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States, 19111-2497
Presbyterian Medical Center
Philadelphia, Pennsylvania, United States, 19104
Pottstown Memorial Regional Cancer Center
Pottstown, Pennsylvania, United States, 19464
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
Reading, Pennsylvania, United States, 19612-6052
Northeast Regional Cancer Institute
Scranton, Pennsylvania, United States, 18510
United States, Texas
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
Fox Chase Cancer Center
Investigators
Principal Investigator: Sharon Manne, PhD Fox Chase Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Fox Chase Cancer Center
ClinicalTrials.gov Identifier: NCT00352638     History of Changes
Obsolete Identifiers: NCT00491205
Other Study ID Numbers: FCCC-FCRB-04-004-P, CDR0000485294, FCCC-00-841
Study First Received: July 13, 2006
Last Updated: May 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Fox Chase Cancer Center:
colon cancer
rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on August 01, 2014